(Q35775369)

10 August 2017

1 reference

title

Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities (English)

1 reference

postmenopausal osteoporosis

10 August 2017

main subject

1 reference

Reginster JY

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Journal of Internal Medicine

10 August 2017

published in

1 reference

10 August 2017

volume

255

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

615-628

1 reference

Epidemiology and outcomes of osteoporotic fractures

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Updated data on proximal femur bone mineral levels of US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Diagnosis of osteoporosis and assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Evaluation of the risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

The Molecular Pharmacology of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Treatment of postmenopausal osteoporosis: an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Oral weekly ibandronate prevents bone loss in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Reconstructing the skeleton with intermittent parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01292.X

10.1111/J.1365-2796.2004.01292.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference